Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University444 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University184 Nanfang Hospital, Southern Medical University138 AstraZeneca136 Guangdong Provincial People's Hospital82
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Guangzhou

3345 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
SanQing Jin
Not applicable
258
Guangzhou
2025-02-20
Recruiting
Peking Union Medical College Hospital
Not applicable
524
Lanzhou, Guangzhou, Cangzhou, Shijiazhuang, Changsha, Changchun, Shanghai, Xianyang
2025-02-20
Recruiting
Zhujiang Hospital
Observational
38
Guangzhou
2025-02-20
Recruiting
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
NCT06676631Refractory Systemic Lupus Erythematosus, Refractory Lupus Nephritis
DrugsNkr-Nk·Rituximab
Guangdong Provincial People's Hospital
Phase 1
18
Guangzhou
2025-02-19
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
876
Guangzhou
2025-02-18
Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
69
Guangzhou
2025-02-17
Active, closed
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
Sun Yat-sen University
Observational
500
Guangzhou
2025-02-15
Not yet open
Guangdong Provincial People's Hospital
Not applicable
55
Guangzhou
2025-02-15
Recruiting
Biocity Biopharmaceutics Co., Ltd.
Phase 3
360
Guangzhou
2025-02-14
Recruiting
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
NCT06716619Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection
DrugSerplulimab
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
32
Guangzhou
2025-02-13
Recruiting
Effect of Low-dose EsketaMine on dElirium in High-risk Elderly Patients uNdergoing elecTive Surgery (ELEMENT)
NCT06817239Delirium in Old Age, Delirium, Postoperative, Anesthesia, Cognitive Dysfunction
DrugEsketamine
Nanfang Hospital, Southern Medical University
Not applicable
1,670
Fuzhou, Guangzhou, Ganzhou
2025-02-12
By invitation
Longboard Pharmaceuticals
Phase 3
324
Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi
2025-02-12
Not yet open
Guangdong Provincial People's Hospital
Not applicable
348
Guangzhou
2025-02-12
Active, closed
ExoRNA Bioscience
Phase 1/2
27
Guangzhou, Chengdu
2025-02-11
Active, closed
AbbVie
Phase 3
468
Beijing, Guangzhou, Shijiazhuang, Wuhan, Suzhou, Xi'an, Taiyuan, Tianjin
2025-02-10
Recruiting
Dianthus Therapeutics
Phase 3
256
Hefei, Guangzhou, Changsha, Chifeng, Suzhou, Beijing, Chengdu, Fujian
2025-02-10
Recruiting
A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke
NCT06712004Ischemic Stroke, Acute, Ischemic Stroke, Cerebral Infarction, Brain Diseases
Zhujiang Hospital
Phase 2
40
Guangzhou
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing
2025-02-07
Active, closed
Genmab
Phase 3
584
Guangzhou, Xi'an, Changchun, Hanzhou, Shanghai, Tianjin, Zhengzhou
2025-02-07
Not yet open
Guangdong Provincial People's Hospital
Not applicable
226
Guangzhou
2025-02-05
Recruiting
BeOne Medicines
Phase 1
120
Guangzhou, Zhengzhou, Shanghai, Tianjin, Hangzhou
2025-02-04
Recruiting
BioNTech SE
Phase 3
621
Changchun, Baoding, Beijing, Bengbu, Fuzhou, Guangzhou, Hangzhou, Ha’erbin
2025-02-03
Recruiting
Guangdong Provincial People's Hospital
Observational
120
Guangzhou
2025-02-01
Recruiting
Chronic Airway Disease and Multimorbidity Cohort
NCT06798077Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
China-Japan Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Shenyang, Xi'an, Shanghai
2025-02-01
Recruiting
Guangdong Provincial People's Hospital
Phase 1/2
161
Guangzhou, Shantou
2025-02-01
Not yet open
Sun Yat-sen University
Phase 2
50
Guangzhou
2025-02-01
By invitation
Guangdong Provincial People's Hospital
Observational
200,000
Guangzhou
2025-02-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
20
Guangzhou
2025-02-01
Recruiting
Beijing Chao Yang Hospital
Not applicable
200
Beijing, Guangzhou, Zhengzhou, Changsha, Shenyang, Shanghai, Taiyuan, Hangzhou
2025-02-01
Not yet open
Nanfang Hospital, Southern Medical University
Phase 4
172
Guangzhou
2025-02
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
68
Fuzhou, Guangzhou, Zhengzhou, Nanchang, Tianjin, Kunming
2025-02
Recruiting
Sinocelltech Ltd.
Phase 1/2
168
Beijing, Changchun, Guangzhou, Hangzhou, Jiujiang, Kunming, Linfen, Mianyang
2025-02
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Fuzhou, Guangzhou, Wuhan, Changsha, Changchun, Shenyang, Xian, Chengdu
2025-01-31
Not yet open
Guangdong Provincial People's Hospital
Not applicable
76
Guangzhou
2025-01-31
Recruiting
Community Exercise Treating Effect on Cardiopulmonary Disease Patients
NCT07154355Coronary Heart Disease (CHD), Heart Failure, Cardiomyopathy, COPD
Guangdong Provincial People's Hospital
Not applicable
200
Guangzhou
2025-01-30
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Beijing, Guangzhou, Jinan, Tianjin, Zhengzhou
2025-01-30
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
135
Bengbu, Wuwei, Guangzhou, Huizhou, Harbin, Luoyang, Nanyang, Zhengzhou
2025-01-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Guiyang
2025-01-27
Recruiting
Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN
NCT06877221Refractory Hypertension or Drug-intolerant Hypertension
Shenzhen Pulsecare Medical Technology Co., Ltd.
Not applicable
204
Guangzhou
2025-01-25
Recruiting
BeOne Medicines
Phase 1/2
258
Beijing, Guangzhou, Suzhou
2025-01-23
Not yet open
Akeso
Phase 3
198
Wuhu, Beijing, Chongqing, Dongguan, Guangzhou, Jiangmen, Shenzhen, Zhuhai
2025-01-23
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
252
Guangzhou
2025-01-22
Active, closed
Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Phase 2
48
Guangzhou
2025-01-22
Active, closed
Yonghong Li
Observational
94
Guangzhou
2025-01-22
Active, closed
Bristol-Myers Squibb
Observational
153
Guangzhou, Handan, Dalian, Shanghai, Beijing
2025-01-20
Recruiting
Safety of Discontinuing NSBBs in Cirrhotic Patients With Managed Primary Aetiological Factors
NCT06549673Portal Hypertension, Cirrhosis, Varices, Esophageal
Chinese University of Hong Kong
Observational
375
Guangzhou, Shanghai
2025-01-20
Recruiting
The Eye Hospital of Wenzhou Medical University
Observational
1,000,000
Guangzhou, Chengdu, Wenzhou
2025-01-19
Recruiting
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
NCT06791512Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum
DrugsMFOLFOX6·Bevacizumab
Jun Huang
Phase 3
166
Guangzhou
2025-01-18
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
27
Guangzhou
2025-01-16
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
456
Guangzhou
2025-01-16
Recruiting
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
NCT06758713Multiple Myeloma, B-cell Lymphoma, Hematological Malignancy
DrugCar-T
The Third Affiliated Hospital of Southern Medical University
Phase 1
60
Guangzhou
2025-01-15
Active, closed
argenx
Phase 3
631
Bengbu, Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Luoyang, Xinxiang
2025-01-15
Recruiting
Dietary Supplements to Treat Radiation-Induced Rectal Injury
NCT06776016Radiotherapy, Radiation Proctitis
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
33
Guangzhou
2025-01-15
Recruiting
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
NCT06855823Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Sun Yat-sen University
Phase 1/2
33
Guangzhou
2025-01-14
Active, closed
Guangzhou Women and Children's Medical Center
Early Phase 1
8
Guangzhou
2025-01-14
Recruiting
Sun Yat-sen University
Phase 1/2
112
Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai, Guilin, Ganzhou, Nanchang
2025-01-10
Recruiting
BeOne Medicines
Phase 1
695
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-01-10
Recruiting
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Active, closed
Janssen Research & Development, LLC
Phase 3
813
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guiyang
2025-01-09
Active, closed
Pfizer
Phase 3
1,035
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Harbin, Wuhan
2025-01-06
Recruiting
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）
NCT06767007Unresectable Locally Recurrent Rectal Cancer
DrugSerplulimab
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
31
Guangzhou
2025-01-06
Active, closed
Guangdong Provincial People's Hospital
Phase 2
138
Guangzhou
2025-01-05
Recruiting
Fluid Responsiveness and Venous Congestion Evolution During Volume Expansion
NCT06772038Hemodynamic, Fluid Responsiveness, Venous Congestion, Fluid Challenge
Bicetre Hospital
Observational
64
Guangzhou, Shenzhen
2025-01-05
Recruiting
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
NCT06764238Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
DrugsBlinatumomab·Methotrexate·Vincristine·Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
1,800
Hefei, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha, Nanjing
2025-01-03
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Observational
16,300
Guangzhou, Zhuhai
2025-01-03
Recruiting
Sun Yat-sen University
Phase 2
47
Guangzhou
2025-01-03
Recruiting
Sun Yat-sen University
Phase 2
76
Lanzhou, Guangzhou, Zhengzhou
2025-01-03
Recruiting
Nanfang Hospital, Southern Medical University
Observational
268
Guangzhou
2025-01-03
Recruiting
Gang Wang
Not applicable
214
Wuhu, Beijing, Guangzhou, Shijiazhuang, Jining, Chengdu, Tianjin, Dali
2025-01-01
Recruiting
HVA vs IA/DA or VA in the Treatment of ND HR-AML
NCT06810791Newly Diagnosed Acute Myeloid Leukemia With High Risk
Nanfang Hospital, Southern Medical University
Phase 3
876
Guangzhou
2025-01-01
Recruiting
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
NCT06900647Metastatic Breast Cancer, Recurrent Breast Cancer
DrugsCDDP·Bortezomib·Cisplatin
Sun Yat-sen University
Phase 1
20
Guangzhou
2025-01-01
By invitation
Nanjing Medical University
Not applicable
500
Beijing, Guangzhou, Nanjing, Chengdu, Shanghai
2025-01-01
Recruiting
Probiotics in Advanced Urothelial Carcinoma
NCT06904573Advanced Urothelial Carcinoma, Probiotics, Immunotherapy
DrugsEnfortumab Vedotin·Disitamab Vedotin·Toripalimab·Nab-paclitaxel
Sun Yat-sen University
Phase 2
222
Guangzhou, Wuhan
2025-01-01
Not yet open
Sun Yat-sen University
Phase 2/3
398
Guangzhou
2025-01-01
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
3,000
Beijing, Guangzhou, Shenzhen, Luoyang, Changsha, Nanjing, Shenyang, Chengdu
2025-01-01
Active, closed
Nanfang Hospital, Southern Medical University
Early Phase 1
30
Guangzhou
2025-01-01
Not yet open
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
NCT06646211Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL)
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-01-01
Not yet open
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
44
Guangzhou
2025-01-01
Recruiting
Guangzhou Institute of Respiratory Disease
Phase 2
120
Guangzhou
2025-01-01
Not yet open
Xiao-dong Zhuang
Phase 4
200
Guangzhou
2025-01-01
By invitation
AI in Respiratory Disease Prevention, Diagnosis, and Triage
NCT06931782Respiratory Diseases, Artificial Intelligence (AI), Randomized Controlled Trial
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
2,400
Guangzhou
2025-01-01
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
62
Guangzhou
2025-01-01
Recruiting
Stereotactic Body Radiation Therapy for Unresectable Locally Recurrent Rectal Cancer
NCT07297004Unresectable Locally Recurrent Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
20
Guangzhou
2025-01-01
Recruiting
Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer
NCT07154173Rectal Neoplasms, Colon Neoplasms, Microbiota, Metagenome
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
300
Guangzhou
2025-01-01
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
84
Guangzhou
2025-01-01
Recruiting
Nanfang Hospital, Southern Medical University
Observational
420
Guangzhou
2025-01-01
Recruiting
Wen-zhao ZHONG
Phase 2
211
Guangzhou
2025-01-01
Not yet open
InnoBM Pharmaceuticals Co., Ltd.
Phase 3
228
Bengbu, Anyang, Zhengzhou, Nanjing, Lishui, Guangzhou, Lanzhou, Luoyang
2025-01
Not yet open
Sinocelltech Ltd.
Phase 1/2
99
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning
2025-01
Not yet open
Guangdong Provincial People's Hospital
Early Phase 1
40
Guangzhou
2025-01
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
400
Guangzhou
2024-12-31
By invitation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
556
Guangzhou, Shantou
2024-12-31
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
198
Guangzhou
2024-12-31
Active, closed
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
258
Chuzhou, Hefei, Huainan, Beijing, Lanzhou, Foshan, Guangzhou, Jiangmen
2024-12-31
Recruiting
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-12-31
Not yet open
Tasly Pharmaceutical Group Co., Ltd
Phase 3
520
Baoding, Beijing, Changsha, Chengde, Chengdu, Guangzhou, Hangzhou, Kaifeng
2024-12-30
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
300
Guangzhou
2024-12-30
Active, closed
Suzhou HepaThera Biotech Co., Ltd.
Phase 1/2
86
Beijing, Xiamen, Guangzhou, Qingyuan, Shanghai, Chengdu
2024-12-30
Active, closed
Boehringer Ingelheim
Phase 2
90
Guangzhou
2024-12-30
Not yet open
Akeso
Phase 2
24
Dongguan, Guangzhou, Shenzhen, Changsha, Ningbo
2024-12-30
Active, closed
Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
NCT06743646Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Phase 3
63
Beijing, Guangzhou, Zhengzhou, Chengdu, Tianjin
2024-12-27
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Zhengzhou, Shanghai, Beijing, Guangzhou
2024-12-27
By invitation
TAF vs TDF During the Pregancy
NCT07542951Hepatitis B Virus Infection; Pregnant Women
The Third Affiliated Hospital of Guangzhou Medical University
Phase 4
210
Guangzhou
2024-12-27
Recruiting
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
NCT06446154Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Anti-angiogenic Therapy, Second-line Treatment
DrugFruquintinib
Sun Yat-sen University
Phase 2
36
Guangzhou
2024-12-27
Recruiting
Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma
NCT06755567Head and Neck Cancer, Neoadjuvant Therapy, Immunotherapy, Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
750
Guangzhou
2024-12-25
Active, closed
First Affiliated Hospital, Sun Yat-Sen University
Observational
700
Guangzhou
2024-12-25
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
20
Guangzhou
2024-12-24
Recruiting
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
420
Bengbu, Wuhu, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhanjiang, Huizhou
2024-12-23
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
200
Guangzhou
2024-12-23
Recruiting
Guangdong Provincial People's Hospital
Phase 2
46
Guangzhou
2024-12-22
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1
12
Beijing, Guangzhou, Hangzhou
2024-12-20
Recruiting
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
NCT06735131Triple-Negative Breast Cancer (TNBC)
DrugToripalimab
Sun Yat-sen University
Phase 2
60
Guangzhou
2024-12-20
Recruiting
Cytokinetics
Phase 3
1,800
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Harbin, Luoyang
2024-12-19
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
DrugsICP-248·Azacitidine
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-12-18
Recruiting
Zhujiang Hospital
Observational
200
Guangzhou
2024-12-17
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
138
Guangzhou, Nanning, Wuhan, Changsha, Nanjing, Jinan, Linyi, Chengdu
2024-12-17
Recruiting
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
NCT06687070Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor
DrugAPG -2449
Ascentage Pharma Group Inc.
Phase 1
90
Guangzhou
2024-12-17
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
438
Guangzhou
2024-12-17
Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Phase 4
700
Guangzhou
2024-12-16
By invitation
Nanfang Hospital, Southern Medical University
Observational
2,334
Guangzhou
2024-12-16
Recruiting
GlaxoSmithKline
Phase 3
520
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai
2024-12-16
Recruiting
Wei XIA, PhD
Not applicable
124
Guangzhou
2024-12-16
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
60
Guangzhou
2024-12-15
Not yet open
Wei XIA, PhD
Observational
1,035
Guangzhou
2024-12-15
Recruiting
Shanghai Mental Health Center
Not applicable
60
Guangzhou, Shijiazhuang, Xinxiang, Nanchang, Taiyuan, Mianyang, Shanghai, Tianjin
2024-12-14
Active, closed
Ausper Biopharma Co., Ltd.
Phase 2
105
Chongqing, Fuzhou, Guangzhou, Changzhou, Zhenjiang, Hangzhou
2024-12-13
Recruiting
Capital Medical University
Phase 3
1,500
Beijing, Fuzhou, Ningde, Putian, Zhangzhou, Guangzhou, Hezhou, Cangzhou
2024-12-13
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Harbin
2024-12-12
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
363
Guangzhou
2024-12-12
Recruiting
Lee's Pharmaceutical Limited
Observational
120
Guangzhou
2024-12-12
Recruiting
Teoxane SA
Not applicable
260
Guangzhou
2024-12-12
Recruiting
Hutchmed
Phase 3
412
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha
2024-12-12
Recruiting
Sun Yat-Sen University Cancer Center
Phase 1/2
10
Guangzhou, Dongguan, Shanghai
2024-12-12
Recruiting
Basilea Pharmaceutica
Phase 3
450
Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang
2024-12-11
Active, closed
Hoffmann-La Roche
Phase 3
350
Beijing, Kunming, Changsha, Chengdu, Guangzhou, Hangzhou, Huizhou, Nanning
2024-12-11
Active, closed
Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer
NCT07046195Hypofractionated Radiotherapy, Triple Negative Breast Cancer (TNBC), Immunotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
250
Guangzhou
2024-12-11
Recruiting
Guangdong Provincial People's Hospital
Phase 1
30
Guangzhou
2024-12-11
Recruiting
Sun Yat-sen University
Phase 2
52
Guangzhou
2024-12-10
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
150
Guangzhou, Shenzhen, Zhengzhou, Nanjing, Nanchang, Shanghai, Xi’an, Chengdu
2024-12-09
By invitation
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
334
Guangzhou
2024-12-09
Recruiting
Long-term Follow-up Study of BRL-101 for TDT
NCT06298630Thalassemia, Beta
Bioray Laboratories
Observational
45
Guangzhou, Shenzhen, Nanning, Changsha, Tianjin, Guangxi
2024-12-08
Recruiting
Pfizer
Phase 3
2,330
Chizhou, Beijing, Xiamen, Guangzhou, Nanning, Changsha, Nanchang, Changchun
2024-12-08
Recruiting
Breathomics in the Diagnosis and Prediction of Radiotherapy-Induced Oropharyngeal Mucositis in Head and Neck Tumors
NCT06767488Head and Neck Tumors, Breathomics, Volatile Organic Compounds, Radiotherapy-induced Oral Mucositis
Nanfang Hospital, Southern Medical University
Observational
375
Guangzhou
2024-12-06
Recruiting
Chipscreen Biosciences, Ltd.
Phase 3
430
Guangzhou
2024-12-06
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
Dongguan, Guangzhou, Jinan
2024-12-06
Recruiting
nVNS for the Prevention and Treatment of Primary Headache
NCT06277063Primary Headache, Migraine in Adolescence, Migraine in Children, Cluster Headache
Nanfang Hospital, Southern Medical University
Not applicable
15
Guangzhou
2024-12-05
Active, closed
Zhujiang Hospital
Early Phase 1
30
Guangzhou
2024-12-05
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Beijing, Changsha, Changzhou, Chengdu, Dazhou, Ganzhou, Guangzhou, Guiyang
2024-12-04
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
116
Chongqing, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha, Wuxi, Changchun
2024-12-04
Recruiting
Shicai Ye
Phase 4
196
Guangzhou, Maoming, Zhanjiang, Sanmenxia
2024-12-02
Not yet open
Guangzhou Institute of Respiratory Disease
Observational
400
Guangzhou
2024-12-01
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou
2024-12-01
Not yet open
A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules
NCT06458673Solitary Lung Nodule, Multiple Pulmonary Nodules
Guangdong Provincial People's Hospital
Observational
1,184
Guangzhou
2024-12-01
Active, closed
Cognitive Function and EEG Brain Network Remodeling Among Users of Hearing Aids With ARHL
NCT06893432Age-related Hearing Loss, Age-related Cognitive Decline, Depression, Sleep Disturbance
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
60
Guangzhou
2024-12-01
Recruiting
Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
NCT06728852Advanced Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Lung Cancer, Third-line and Beyond Therapy, Angiogenesis Inhibition in Oncology
Li-kun Chen
Phase 2
32
Guangzhou
2024-12-01
Recruiting
Guangzhou Institute of Respiratory Disease
Phase 2
30
Guangzhou
2024-12-01
Recruiting
Y-90 SIRT for Unresectable HCC Larger Than 7cm
NCT06707233Hepatocellular Carcinoma Non-Resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
33
Guangzhou
2024-12-01
Recruiting
Sun Yat-sen University
Phase 2
97
Guangzhou
2024-12-01
Recruiting
Hospital of Stomatology, Sun Yat-Sen University
Not applicable
142
Guangzhou
2024-11-30
Recruiting
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT06734702Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy, Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 3
497
Guangzhou
2024-11-30
Recruiting
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
NCT06719700Toripalimab, Surufatinib, Chemoradiotherapy, Limited-stage Small Cell Lung Cancer (LS-SCLC)
Sun Yat-sen University
Phase 2
47
Guangzhou
2024-11-30
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
498
Guangzhou
2024-11-29
Recruiting
Zhujiang Hospital
Phase 2/3
30
Guangzhou
2024-11-29
Active, closed
Santen Pharmaceutical Co., Ltd.
Phase 3
345
Beijing, Guangzhou, Guiyang, Hangzhou, Heilongjiang, Jinan, Lanzhou, Luoyang
2024-11-28
Recruiting
BeOne Medicines
Phase 1/2
80
Fuzhou, Guangzhou, Suzhou, Hangzhou, Wenzhou
2024-11-27
Recruiting
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
420
Guangzhou
2024-11-27
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin
2024-11-27
Recruiting
Sun Yat-sen University
Phase 3
242
Guangzhou
2024-11-27
Recruiting
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
115
Guangzhou
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-11-27
Not yet open
Guangzhou Ruixin Biotechnological Co., LTD
Early Phase 1
10
Guangzhou
2024-11-25
Not yet open
Sun Yat-sen University
Phase 2/3
206
Guangzhou
2024-11-25
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 3
524
Guangzhou
2024-11-22
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
UCB Biopharma SRL
Phase 3
450
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou
2024-11-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
182
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-11-20
Recruiting
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
NCT07602049Soft Tissue Sarcoma (STS), Osteosarcoma
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-11-20
Recruiting
A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
NCT06829147Nasopharyngeal Cancinoma (NPC), Lymph Node Metastasis
Sun Yat-sen University
Observational
500
Guangzhou
2024-11-19
Active, closed
Daiichi Sankyo
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Jinan, Nanchang, Nanjing
2024-11-19
Recruiting
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2024-11-18
Recruiting
Tissue-resident Immune Cell Subsets in aGVHD
NCT06708507Acute Graft-versus-Host Disease, Hematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University
Observational
40
Guangzhou
2024-11-16
Recruiting
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
NCT06568471Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
DrugLerodalcibep
Hasten Biopharmaceutical Co., Ltd.
Phase 3
210
Beijing, Guangzhou, Shijiazhuang, Daqing, Changsha, Nanchang, Binzhou, Heze
2024-11-16
Active, closed
Pfizer
Phase 3
636
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Recruiting
Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab
NCT06652113Recurrent Pregnancy Loss, Euthyroid With Thyroid Antibodies
DrugLevothyroxine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
796
Guangzhou
2024-11-15
Recruiting
Guangdong Provincial People's Hospital
Phase 4
384
Guangzhou
2024-11-14
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
552
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shaoguan
2024-11-14
Active, closed
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
482
Bengbu, Hefei, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou
2024-11-14
Not yet open
Sir Run Run Shaw Hospital
Phase 2
76
Fuzhou, Guangzhou, Shanghai, Hangzhou
2024-11-14
Recruiting
Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices
NCT06652750Sick Sinus Syndrome, Atrioventricular Block, Second and Third Degree, Heart Failure
The Third People's Hospital of Chengdu
Not applicable
688
Guangzhou, Chengdu
2024-11-13
Recruiting
Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL
NCT06985472Initial MZL, Untreated MZL, BTKi, CD20
Li Zhiming
Phase 2
33
Guangzhou
2024-11-13
By invitation
Multicenter Prospective Cohort Study of Hypertriglyceridemia Acute Pancreatitis
NCT06976099Acute Pancreatitis (AP), Hypertriglyceridemia Acute Pancreatitis
Peking Union Medical College Hospital
Observational
1,000
Beijing, Guangzhou, Zunyi, Harbin, Changsha, Nanjing, Yangzhou, Dalian
2024-11-13
Active, closed
AbbVie
Observational
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Dalian, Xi'an, Qingdao
2024-11-13
Recruiting
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
NCT06742502Primary Mediastinal Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Phase 2
30
Fuzhou, Guangzhou
2024-11-12
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
60
Fuyang, Hefei, Chongqing, Lanzhou, Guangzhou, Nanning, Zhengzhou, Changsha
2024-11-12
Active, closed
GlaxoSmithKline
Phase 2
283
Beijing, Chengdu, Guangzhou, Shanghai
2024-11-11
Recruiting
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3
170
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Guangzhou, Shenzhen, Zhujiang
2024-11-11
Recruiting
Ascentage Pharma Group Inc.
Phase 3
40
Guangzhou
2024-11-11
Recruiting
A Real World Study About PMN
NCT06893328Primary Membranous Nephropathy
Wei Chen
Observational
200
Guangzhou
2024-11-11
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi
2024-11-11
Active, closed
Sanofi
Phase 2
556
Beijing, Changchun, Chengde, Chengdu, Foshan, Guangzhou, Guiyang, Hangzhou
2024-11-07
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
80
Beijing, Lanzhou, Guangzhou, Guigang, Nanning, Harbin, Anyang, Puyang
2024-11-06
Recruiting
Non-Helium Magnetoencephalography in Pediatric Refractory Epilepsy
NCT07064421Refractory Epilepsy in Children
Guangzhou Women and Children's Medical Center
Observational
100
Guangzhou
2024-11-05
Recruiting
Non-Helium Magnetoencephalography in Autism Spectrum Disorder
NCT07064967Autism Spectrum Disorder (ASD)
Guangzhou Women and Children's Medical Center
Observational
80
Guangzhou
2024-11-05
Recruiting
Guangzhou Women and Children's Medical Center
Observational
100
Guangzhou
2024-11-05
Recruiting
Sun Yat-sen University
Observational
2
Guangzhou
2024-11-04
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
90
Guangzhou
2024-11-04
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
180
Hefei, Fuzhou, Xiamen, Guangzhou, Nanning, Zhengzhou, Shanghai, Taiyuan
2024-11-03
Not yet open
Sun Yat-sen University
Phase 2
55
Guangzhou
2024-11-02
Recruiting
Sun Yat-sen University
Phase 2
120
Guangzhou
2024-11-01
Recruiting
Sun Yat-sen University
Observational
200
Guangzhou
2024-11-01
Recruiting
Sun Yat-sen University
Phase 1
30
Guangzhou
2024-11-01
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
60
Guangzhou
2024-11-01
Active, closed
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
200
Guangzhou
2024-11-01
Recruiting
Sun Yat-sen University
Phase 2
39
Guangzhou, Lanzhou, Dongguan, Shantou, Shenzhen, Zhaoqing, Zhuhai
2024-11-01
Recruiting
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
NCT06520683Colorectal Cancer, Microsatellite Instability High
DrugTislelizumab
Sun Yat-sen University
Phase 3
180
Guangzhou
2024-11-01
Recruiting
Sun Yat-sen University
Not applicable
40
Guangzhou, Dongguan
2024-11-01
Not yet open
Guangdong Association of Clinical Trials
Not applicable
342
Dongguan, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2024-11
Not yet open
Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
Phase 1
100
Guangzhou
2024-11
Recruiting
Brii Biosciences Limited
Phase 2
250
Beijing, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-10-31
By invitation
Han Ying
Phase 2/3
244
Guangzhou, Xi'an
2024-10-30
Active, closed
Sun Yat-sen University
Phase 2
42
Guangzhou
2024-10-30
Recruiting
Treating Loneliness In The Older Adult With Depression With tDCS
NCT06658795Major Depressive Disorder, Loneliness
Guangzhou Psychiatric Hospital
Not applicable
180
Guangzhou
2024-10-29
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
308
Dongguan, Foshan, Guangzhou
2024-10-28
Recruiting
Comparing the Efficacy of Domestic Versus Imported Hearing Aids in ARHL
NCT06882889Age-related Hearing Loss, Hearing Loss, Sensorineural
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
80
Guangzhou
2024-10-24
Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Hefei, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Chengde, Harbin
2024-10-24
Active, closed
Eli Lilly and Company
Phase 3
1,400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hefei, Jinan, Luoyang
2024-10-24
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
59
Guangzhou
2024-10-23
Recruiting
Shanghai JMT-Bio Inc.
Phase 3
516
Guangzhou
2024-10-23
Recruiting
Sun Yat-sen University
Phase 2
12
Guangzhou
2024-10-23
Recruiting
Sun Yat-sen University
Phase 2
73
Guangzhou
2024-10-23
Recruiting
Pfizer
Phase 3
900
Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou
2024-10-22
Recruiting
AstraZeneca
Observational
200
Guangzhou, Hong Kong, Shenzhen, Zhongshan, Zhuhai
2024-10-22
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
320
Guangzhou, Maoming
2024-10-22
Recruiting
Sun Yat-sen University
Phase 2
84
Guangzhou
2024-10-22
Active, closed
Pfizer
Phase 3
609
Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Guilin, Wuhan
2024-10-21
Recruiting
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Huizhou, Nanchang
2024-10-18
Active, closed
GlaxoSmithKline
Phase 2
23
Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Kunming, Shanghai
2024-10-17
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
364
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning
2024-10-16
Recruiting
Yang Hong
Phase 3
360
Guangzhou
2024-10-15
By invitation
Sun Yat-sen University
Not applicable
252
Guangzhou
2024-10-15
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
542
Bengbu, Hefei, Beijing, Quanzhou, Zhangzhou, Lanzhou, Wuwei, Guangzhou
2024-10-11
Recruiting
Sinocelltech Ltd.
Phase 1/2
441
Guangzhou
2024-10-10
Recruiting
Bio-Thera Solutions
Phase 3
406
Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Shenzhen, Nanning, Zunyi
2024-10-09
Recruiting
Fei Gao
Phase 2
40
Guangzhou
2024-10-08
Active, closed
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
500
Bengbu, Tongling, Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen
2024-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou
2024-10-07
Recruiting
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Recruiting
Guangzhou Women and Children's Medical Center
Phase 1
10
Guangzhou
2024-10-01
Recruiting
Guangdong Provincial People's Hospital
Phase 2
252
Guangzhou
2024-10-01
By invitation
Guangzhou Panyu Central Hospital
Observational
100
Guangzhou
2024-10-01
Recruiting
Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia
NCT06734520Thalassemia Majors (Beta-Thalassemia Major), Haplo-identical Donors
Guangzhou Women and Children's Medical Center
Not applicable
3
Guangzhou
2024-10-01
Recruiting
Nanfang Hospital, Southern Medical University
Observational
1,000
Guangzhou
2024-10-01
By invitation
Sanofi
Phase 2
900
Beijing, Changchun, Changsha, Chengde, Guangzhou, Guiyang, Hefei, Hohhot
2024-09-30
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
669
Guangzhou, Yixingcun
2024-09-30
Recruiting
Safety and Efficacy of CG-BM1 in Ischemic Stroke
NCT07896941Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
GuangZhou Cellgenes Biotechnology Co., Ltd.
Phase 1/2
87
Guangzhou
2024-09-30
Active, closed
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Phase 4
116
Guangzhou
2024-09-30
Recruiting
Bactiseal Catheter Safety Registry Study
NCT06276543Hydrocephalus
Integra LifeSciences Corporation
Observational
200
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu
2024-09-29
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
192
Guangzhou
2024-09-27
Active, closed
AstraZeneca
Observational
1,199
Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan
2024-09-26
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Xi'an, Shanghai
2024-09-26
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Jiaxing
2024-09-26
Active, closed
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma
NCT06630780Head and Neck Squamous Cell Carcinoma (HNSCC)
Sun Yat-sen University
Not applicable
50
Guangzhou
2024-09-26
Active, closed
Longboard Pharmaceuticals
Phase 3
108
Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi
2024-09-25
Recruiting
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301B-cell Acute Lymphoblastic Leukemia
DrugYK012
Excyte Biopharma Ltd
Phase 1/2
46
Guangzhou, Guiyang, Zhengzhou, Xuzhou, Nanchang, Changchun, Dalian, Shenyang
2024-09-25
Recruiting
Nanfang Hospital, Southern Medical University
Phase 1
12
Guangzhou
2024-09-25
Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
60
Guangzhou
2024-09-24
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
876
Guangzhou
2024-09-23
Active, closed
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
112
Guangzhou
2024-09-21
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xi’an, Chengdu, Hangzhou, Huzhou
2024-09-21
Recruiting
Sun Yat-sen University
Phase 3
422
Guangzhou, Guilin, Changsha, Nanjing
2024-09-20
Not yet open
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
60
Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang
2024-09-20
Not yet open
Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer
NCT06617052Locally Recurrent Rectal Cancer, Preoperative Chemoradiotherapy
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
100
Guangzhou
2024-09-19
By invitation
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
NCT06437288Esophageal Cancer, Photodynamic Therapy
Sun Yat-sen University
Phase 4
198
Guangzhou
2024-09-18
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
Active, closed
argenx
Phase 3
141
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai
2024-09-18
Active, closed
Hoffmann-La Roche
Phase 3
400
Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou
2024-09-17
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
190
Hefei, Beijing, Guangzhou, Shenzhen, Shijiazhuang, Nanchang, Pudong, Shanghai
2024-09-17
Active, closed
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
Recruiting
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 2/3
254
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Kaifeng, Wuhan, Huai'an
2024-09-14
Recruiting
GlaxoSmithKline
Phase 3
440
Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai
2024-09-11
Recruiting
Sun Yat-sen University
Phase 2
35
Guangzhou
2024-09-11
Recruiting
Eighth Affiliated Hospital, Sun Yat-sen University
Phase 3
477
Guangzhou, Puning, Shenzhen, Xiangyang
2024-09-10
Recruiting
Zhujiang Hospital
Not applicable
126
Guangzhou
2024-09-10
Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558Community-acquired Pneumonia
Shanghai SIMR Biotechnology Co., Ltd.
Phase 2
240
Fuyang, Beijing, Zhangzhou, Gaozhou, Guangzhou, Shantou, Yulin, Shijiazhuang
2024-09-10
Active, closed
Takeda
Phase 3
2,099
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai
2024-09-04
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Active, closed
Li-kun Chen
Phase 2
70
Guangzhou
2024-09-04
Recruiting
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Active, closed
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 3
72
Beijing, Chongqing, Guangzhou, Changsha, Nanjing, Qingdao, Shanghai, Xi’an
2024-09-03
Recruiting
Sun Yat-sen University
Phase 1
16
Guangzhou
2024-09-03
Active, closed
Nanfang Hospital, Southern Medical University
Observational
17
Guangzhou
2024-09-01
Recruiting
OSAHS Screening in Diverse Populations
NCT07736872Obstructive Sleep Apnea (OSA), Snoring, Prevalence, Questionnaires and Surveys
Kang Wu
Observational
100,000
Guangzhou, Anshun
2024-09-01
Recruiting
Zhou Chengzhi
Phase 1/2
20
Guangzhou
2024-09-01
Not yet open
Phase 1 Trial of KH801
NCT06364501Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.
Phase 1
17
Beijing, Guangzhou, Jinan, Chengdu
2024-09-01
Recruiting
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Not yet open
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
NCT06567600Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2
43
Guangzhou
2024-09-01
Recruiting
Guangzhou Medical University
Observational
1,000
Guangzhou
2024-09-01
Recruiting
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
NCT06467799Hepatocellular Carcinoma, Beyond Milan Criteria
Sun Yat-sen University
Phase 2
39
Guangzhou
2024-09-01
By invitation
Nanfang Hospital, Southern Medical University
Observational
1,500
Guangzhou
2024-09-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
130
Foshan, Guangzhou, Jieyang, Shantou
2024-09-01
Recruiting
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
NCT06864221Hepatocellular Carcinoma, Radiotherapy, Treatment Outcome, Biomarkers
Nanfang Hospital, Southern Medical University
Observational
260
Guangzhou
2024-09-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
20
Guangzhou
2024-09
Active, closed
Guangdong Provincial People's Hospital
Observational
330
Guangzhou
2024-08-30
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
27
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
2024-08-29
Active, closed
Rui He
Not applicable
240
Guangzhou
2024-08-28
Recruiting
Bayer
Phase 3
444
Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Wuhan, Changsha
2024-08-28
Recruiting
BeBetter Med Inc
Phase 2
30
Guangzhou
2024-08-28
Active, closed
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan
2024-08-28
Recruiting
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
NCT06581315Hepatocellular Carcinoma, Adjuvant Therapy
DrugDonafenib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
204
Guangzhou
2024-08-28
Active, closed
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Recruiting
Sun Yat-Sen University Cancer Center
Observational
50
Guangzhou
2024-08-26
Not yet open
Guangdong Provincial People's Hospital
Not applicable
98
Guangzhou
2024-08-25
By invitation
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
NCT06712017Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
GrandPharma (China) Co., Ltd.
Observational
100
Guangzhou, Jinan, Xi’an, Beijing, Shanghai
2024-08-22
Recruiting
Sanofi
Phase 3
160
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Jiazhuang, Jinan, Nanchang
2024-08-21
Recruiting
Guangdong Provincial People's Hospital
Phase 2
240
Dongguan, Foshan, Guangzhou, Shenzhen, Zhanjiang, Zhuhai, Haikou
2024-08-21
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
122
Guangzhou
2024-08-20
Active, closed
Oneness Biotech Co., Ltd.
Phase 2/3
120
Jiangmen, Luoyang, Suzhou, Zhenjiang, Shenyang, Xi'an, Hangzhou, Guangzhou
2024-08-16
Active, closed
Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study
NCT06461338Non-small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
Guangzhou University of Traditional Chinese Medicine
Not applicable
60
Guangzhou, Nanjing
2024-08-15
Active, closed
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Recruiting
Chengcheng Guo
Phase 2
40
Guangzhou
2024-08-13
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
100
Guangzhou
2024-08-13
Recruiting
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
140
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Shanghai
2024-08-13
Recruiting
Guangdong Provincial People's Hospital
Phase 4
39
Guangzhou
2024-08-10
Recruiting
Sun Yat-sen University
Not applicable
1,200
Guangzhou
2024-08-10
Recruiting
Shenzhen Pulsecare Medical Technology Co., Ltd.
Not applicable
6
Guangzhou
2024-08-08
Active, closed
AbbVie
Phase 3
111
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
722
Guangzhou
2024-08-07
Active, closed
Pfizer
Observational
450
Beijing, Changchun, Changsha, Guangzhou, Shanghai
2024-08-07
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 2
120
Guangzhou
2024-08-07
Recruiting
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
DrugsJAB-3312·Glecirasib·Pemetrexed·Tislelizumab
Allist Pharmaceuticals, Inc.
Phase 3
392
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Cangzhou, Haerbin
2024-08-07
By invitation
Guangdong Provincial People's Hospital
Not applicable
60
Guangzhou
2024-08-06
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
270
Fuzhou, Foshan, Guangzhou, Jiangmen, Shenzhen, Nanning, Zunyi, Harbin
2024-08-06
Active, closed
Amgen
Phase 4
102
Beijing, Chongqing, Guangzhou, Harbin, Huaian, Nanjing, Suzhou, Xuzhou
2024-08-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Beijing, Chongqing, Guangzhou, Huizhou, Shenzhen, Jingzhou, Wuhan, Changsha
2024-08-05
Recruiting
Sun Yat-sen University
Phase 1
24
Guangzhou
2024-08-02
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,500
Guangzhou, Wuhan, Yangzhou, Shenyang, Chengdu, Hangzhou
2024-08-01
Recruiting
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
NCT05387031Crohn Disease, Stricture; Bowel, Intestinal Stricture
DrugUstekinumab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
239
Beijing, Chongqing, Guangzhou, Huai'an, Suzhou, Yangzhou, Hangzhou
2024-08-01
Recruiting
Guangdong Provincial People's Hospital
Phase 3
310
Guangzhou
2024-08-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
804
Guangzhou, Shantou
2024-08-01
Recruiting
Nanfang Hospital, Southern Medical University
Phase 4
580
Guangzhou
2024-08-01
Recruiting
Sun Yat-sen University
Phase 3
490
Guangzhou
2024-08-01
Not yet open
Stem Cell Derived Exome for Treatment of Diabetic Foot
NCT06480123Diabetic Foot, Stem Cell
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2
50
Guangzhou
2024-08-01
Recruiting
Nanfang Hospital, Southern Medical University
Observational
800
Guangzhou
2024-08-01
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 3
178
Guangzhou
2024-08-01
Active, closed
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
NCT06282874Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
DrugLorlatinib
Guangdong Association of Clinical Trials
Phase 4
41
Dongguan, Foshan, Guangzhou
2024-08-01
Recruiting
Sun Yat-sen University
Phase 2
42
Guangzhou, Shanghai
2024-08-01
Recruiting
Xiang Gao
Not applicable
184
Guangzhou
2024-08-01
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Hefei, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Xi'an, Xianyang
2024-07-31
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
320
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Dalian, Jinan, Xi’an
2024-07-31
Active, closed
magAssist, Inc.
Not applicable
236
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Lanzhou, Shanghai, Taiyuan
2024-07-31
Recruiting
Xintian Pharmaceutical
Phase 4
234
Chongqing, Xiamen, Guangzhou, Shenzhen, Shunde, Wuhan, Nanjing, Xuzhou
2024-07-30
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
216
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanning, Nantong, Qingdao
2024-07-30
Recruiting
Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation
NCT06308952Cerebrovascular Event, Stent Stenosis, Ischemic Stroke, Hemorrhagic Stroke
DrugsLipitor·Atorvastatin
Duan Chuanzhi
Phase 4
354
Guangzhou
2024-07-30
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
10,000
Guangzhou
2024-07-26
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
280
Guangzhou
2024-07-24
Recruiting
Sun Yat-sen University
Observational
30
Guangzhou
2024-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Nanning
2024-07-24
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Guangzhou
2024-07-24
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Beijing, Guangzhou, Zhengzhou, Shenyang, Jinan, Shanghai
2024-07-24
Active, closed
Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma
NCT06524466Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage
Sun Yat-sen University
Phase 2
35
Guangzhou
2024-07-23
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
DrugAdebrelimab
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
214
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Qingyuan
2024-07-23
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1/2
630
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-07-23
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
102
Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Jiangmen
2024-07-22
Recruiting
Born In Guangzhou Intervention Study
NCT05503849Pregnancy Outcomes, Child Development, Pregnancy Complications
Guangzhou Women and Children's Medical Center
Not applicable
1,160
Guangzhou
2024-07-22
Not yet open
Plasmodium Immunotherapy for Advanced Ovarian Cancer
NCT05924776Advanced Ovarian Cancer
CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.
Phase 2/3
30
Guangzhou
2024-07-20
Recruiting
GlaxoSmithKline
Phase 3
150
Guangzhou, Shanghai, Tianjin
2024-07-19
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
21
Guangzhou
2024-07-18
Recruiting
Sun Yat-sen University
Phase 2
34
Guangzhou
2024-07-18
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
60
Beijing, Changsha, Changzhi, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-07-17
Active, closed
Vor Biopharma
Phase 3
191
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zunyi, Wuhan
2024-07-17
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-07-17
Recruiting
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
NCT06517953Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q, EGFR S768I
DrugsIcotinib·Befotertinib
Sun Yat-sen University
Phase 2
23
Guangzhou
2024-07-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Bengbu, Hefei, Beijing, Chongqing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang
2024-07-16
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
132
Guangzhou
2024-07-16
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 4
214
Guangzhou
2024-07-15
Recruiting
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
NCT06197776Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma, Efficacy of Chemoradiotherapy and Immunotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2024-07-15
Recruiting
Sun Yat-sen University
Phase 2
148
Guangzhou
2024-07-15
Recruiting
Nanfang Hospital, Southern Medical University
Phase 2
40
Guangzhou
2024-07-14
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Shanghai
2024-07-12
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang
2024-07-12
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2
90
Beijing, Bengbu, Changsha, Fuzhou, Guangzhou, Jinan, Kunming, Nanning
2024-07-11
Active, closed
Guangdong Provincial People's Hospital
Phase 4
52
Guangzhou
2024-07-10
Not yet open
Rui-hua Xu, MD, PhD
Phase 2
70
Guangzhou
2024-07-10
Recruiting
Colorado Prevention Center
Phase 3
1,500
Guangzhou, Changsha, Jinan, Shanghai, Taiyuan, Xian City, Chengdu, Tianjin
2024-07-09
Recruiting
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT06500676KRAS G12D Mutations, Advanced Solid Tumors
DrugCetuximab
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
407
Hefei, Beijing, Guangzhou, Nanning, Haerbin, Zhengzhou, Wuhan, Changsha
2024-07-09
Active, closed
Novartis Pharmaceuticals
Phase 4
318
Hefei, Fuzhou, Guangzhou, Shenzhen, Zunyi, Harbin, Zhengzhou, Wuhan
2024-07-09
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
156
Guangzhou, Zhengzhou, Wuhan, Changsha, Shang'ai, Shanghai, Chengdu, Hangzhou
2024-07-09
Recruiting
Lingyi Biotech Co., Ltd.
Phase 1/2
12
Guangzhou, Taiyuan, Tianjin
2024-07-05
Active, closed
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Zhengzhou, Wuhan, Xian, Hangzhou, Beijing, Taian, Tianjin
2024-07-04
Not yet open
Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage
NCT06272565Diabetic Retinopathy, Diabetic Macular Edema, Anti-vascular Endothelial Growth Factor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
240
Guangzhou
2024-07-03
Recruiting
Yizhuo Zhang
Phase 2
110
Guangzhou
2024-07-03
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4
134
Guangzhou
2024-07-01
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
104
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming
2024-07-01
Recruiting
Nanfang Hospital, Southern Medical University
Observational
900
Guangzhou
2024-07-01
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
DrugPembrolizumab
Eli Lilly and Company
Phase 1
460
Beijing, Guangzhou, Shanghai
2024-07-01
Recruiting
The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
NCT06988579Lung Cancer, Artificial Intelligence (AI), Randomized Controlled Trial
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
7,294
Guangzhou
2024-07-01
Recruiting
The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System.
NCT07330362Chronic Glomerulonephritis, Chronic Kidney Disease
Zhujiang Hospital
Observational
2,900
Guangzhou
2024-07-01
Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Observational
400
Guangzhou
2024-07-01
Recruiting
Deep Learning-based sbORN Diagnostic Model
NCT06463392Nasopharyngeal Carcinoma, Herpesvirus 4, Human
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
312
Guangzhou
2024-07-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
420
Hefei, Fuzhou, Lanzhou, Guangzhou, Huizhou, Jiangmen, Meizhou, Guigang
2024-07
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
30
Guangzhou
2024-07
Recruiting
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
90
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jinan, Kunming
2024-06-30
Recruiting
ChromX Health
Observational
10,000
Guangzhou
2024-06-30
Recruiting
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
NCT06518655Pulmonary Nodules, Multiple, Pulmonary Nodules, Solitary, Lung Cancer
ChromX Health
Observational
3,000
Beijing, Foshan, Guangzhou, Wuhan, Shanghai, Chengdu
2024-06-30
Active, closed
AstraZeneca
Phase 3
339
Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Heilongjiang, Jinan
2024-06-29
Active, closed
Nanfang Hospital, Southern Medical University
Not applicable
50
Guangzhou
2024-06-28
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
140
Guangzhou, Zhuhai, Chengde, Harbin, Changsha, Changzhou, Binzhou, Shanghai
2024-06-27
Recruiting
Beijing 302 Hospital
Phase 2
140
Lanzhou, Guangzhou, Sanya, Wuhan, Shanghai, Kashgar, Beijing
2024-06-27
Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
230
Guangzhou
2024-06-26
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
570
Guangzhou
2024-06-25
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
316
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Changsha, Nanjing, Shanghai
2024-06-25
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Anhui Sheng, Beijing, Guangzhou, Zunyi, Shijiazhuang, Zhengzhou, Changsha, Wuhan
2024-06-25
Recruiting
Early Intervention Strategies for Lung Cancer
NCT06988943Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
16,000
Guangzhou
2024-06-25
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guiyang, Shijiazhuang
2024-06-25
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Cangzhou, Shijiazhuang, Harbin
2024-06-25
Recruiting
Guangdong Provincial People's Hospital
Phase 2
25
Guangzhou
2024-06-22
Active, closed
Lyvgen Biopharma Holdings Limited
Phase 2
64
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2024-06-21
Recruiting
AstraZeneca
Phase 3
240
Beijing, Chongqing, Dongguan, Guangzhou, Hangzhou, Hengyang, Jining, Nanjing
2024-06-20
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
9
Beijing, Guangzhou, Shijiazhuang, Shenyang, Chengdu, Hangzhou
2024-06-19
Recruiting
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
NCT06341400Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Zhujiang Hospital
Phase 1/2
55
Guangzhou
2024-06-19
Recruiting
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1
30
Guangzhou, Zhengzhou, Jinan
2024-06-19
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
83
Guangzhou
2024-06-19
Active, closed
Celgene
Phase 3
850
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou
2024-06-19
Recruiting
Sun Yat-sen University
Phase 2
216
Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang
2024-06-18
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
DrugAMT-676
Multitude Therapeutics Inc.
Early Phase 1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Active, closed
Hoffmann-La Roche
Phase 3
68
Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan
2024-06-17
Recruiting
the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children
NCT05911893Malnutrition, Child, Malnourishment, Nutritional Deficiency, Undernutrition
Children's Hospital of Chongqing Medical University
Not applicable
200
Hefei, Beijing, Jilin City, Chongqing, Guangzhou, Guiyang, Changsha, Nanjing
2024-06-17
Recruiting
Peking University People's Hospital
Phase 2
20
Beijing, Guangzhou
2024-06-15
Recruiting
RemeGen Co., Ltd.
Phase 1/2
24
Guangzhou, Wuhan, Changsha, Nanjing, Chengdu, Tianjin
2024-06-14
Recruiting
Hangzhou Sumgen Biotech Co., Ltd.
Phase 3
360
Beijing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Suzhou, Taiyuan, Xi’an
2024-06-14
Recruiting
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06574568Relapsed or Refractory Multiple Myeloma
DrugYKST02
Excyte Biopharma Ltd
Phase 1
70
Beijing, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Dalian, Jinan
2024-06-14
Active, closed
Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer
NCT07371910Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer
DrugApatinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
200
Guangzhou
2024-06-12
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
200
Guangzhou
2024-06-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2024-06-11
Active, closed
Biotheus Inc.
Phase 3
392
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou
2024-06-11
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
42
Guangzhou
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
90
Guangzhou
2024-06-10
Recruiting
Sun Yat-sen University
Phase 1/2
82
Guangzhou
2024-06-06
Active, closed
Nanfang Hospital, Southern Medical University
Phase 2
30
Guangzhou
2024-06-06
Recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
369
Guangzhou
2024-06-06
Recruiting
Mobile Applet for Weight Management in Obese Heart Failure Patients
NCT06455878Heart Failure, Overweight and Obesity, Weight Loss, Heart Failure With Reduced Ejection Fraction
Heart Health Research Center
Not applicable
830
Beijing, Guangzhou, Langfang, Jixi, Luoyang, Shangqiu, Xinyang, Zhengzhou
2024-06-06
Recruiting
AstraZeneca
Observational
850
Beijing, Changsha, Chengdu, Guangzhou, Hefei, Nanjing, Nanning, Shanghai
2024-06-05
Active, closed
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
Juventas Cell Therapy Ltd.
Observational
200
Beijing, Guangzhou, Zhengzhou, Wuhan, Xuzhou, Jinan, Shanghai, Chengdu
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2024-06-05
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2024-06-04
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin, Anyang, Zhengzhou
2024-06-04
Recruiting
The First Affiliated Hospital of Zhengzhou University
Observational
15,000
Anyang, Guangzhou, Hebi, Jiaozuo, Jiayuguan, Jinan, Jiyuan, Kaifeng
2024-06-03
Recruiting
Nanfang Hospital, Southern Medical University
Phase 2
92
Guangzhou
2024-06-01
Recruiting
Hemodynamic Study of In-Stent Stenosis(I) After Flow Diverter(F) Based on 3D-DSA(D) Combined With TCCD(T)
NCT06448949Hemodynamics;In-stent Stenosis;Transcranial Doppler;Intracranial Aneurysm;Flow Diverter; Prospective Cohort Study
Zhujiang Hospital
Observational
200
Guangzhou
2024-06-01
Not yet open
Zhujiang Hospital
Observational
152
Foshan, Guangzhou, Guanzhou
2024-06-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
106
Guangzhou
2024-06-01
Not yet open
A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
NCT06422637Liquid Biopsy for Early Screening of Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
5,944
Guangzhou
2024-06-01
Recruiting
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
NCT06449833Type2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease
Zhujiang Hospital
Phase 4
100
Guangzhou
2024-06
Not yet open
Henagliflozin's Impact on Prediabetes Remission
NCT06448130PreDiabetes, Prediabetic State, Type 2 Diabetes, Glucose Metabolism Disorders
DrugHenagliflozin
Shandong Provincial Hospital
Phase 4
984
Chuzhou, Hefei, Fuzhou, Lanzhou, Foshan, Guangzhou, Guanzhou, Shenzhen
2024-06
Recruiting
XIANG YANQUN
Phase 3
164
Guangzhou
2024-05-30
Active, closed
A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors
NCT07131189Locally Advanced/Metastatic Solid Tumors
DrugFL115
Suzhou Forlong Biotechnology Co., Ltd
Phase 1
30
Beijing, Guangzhou, Jinan
2024-05-30
Recruiting
Sun Yat-sen University
Observational
908
Fuzhou, Guangzhou, Zhongshan, Nanning, Wuzhou
2024-05-29
Recruiting
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor
NCT06350006CLDN18.2-positive Advanced Solid Tumor
DrugsSHR-A1904·Folfox·Adebrelimab
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
924
Guangzhou
2024-05-29
Active, closed
Amgen
Phase 1
120
Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun
2024-05-29
Active, closed
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL
Janssen Research & Development, LLC
Phase 1
58
Beijing, Guangzhou, Hangzhou, Shanghai, Tianjin
2024-05-28
Recruiting
Intratumoral CAN2109 in Subjects With Solid Tumors
NCT06332430Solid Tumor, Lymphoma
Canwell Biotech Limited
Phase 1
27
Guangzhou
2024-05-28
Recruiting
The Affiliated Hospital Of Guizhou Medical University
Not applicable
396
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanning, Guiyang, Kaili
2024-05-27
Recruiting
Hutchmed
Phase 1
132
Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan
2024-05-27
Recruiting
Kind Pharmaceuticals LLC
Phase 2
64
Guangzhou, Maoming, Liuzhou, Nanning, Haikou
2024-05-27
Recruiting
Sun Yat-sen University
Phase 2/3
84
Guangzhou
2024-05-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi
2024-05-24
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Beijing, Fuzhou, Guangzhou, Zhengzhou, Nanjing, Tianjin, Hanzhou
2024-05-24
Recruiting
Sun Yat-sen University
Phase 2
38
Guangzhou
2024-05-23
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
432
Guangzhou
2024-05-22
Recruiting
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
NCT06542159Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
Sun Yat-sen University
Phase 2
130
Guangzhou
2024-05-22
Recruiting
Guangdong Provincial People's Hospital
Phase 2
45
Guangzhou
2024-05-22
Active, closed
XIANG YANQUN
Phase 2
38
Guangzhou
2024-05-22
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 4
232
Guangzhou
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi
2024-05-21
Active, closed
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Recruiting
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT06516133Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
494
Guangzhou
2024-05-17
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
226
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-05-15
Recruiting
XIANG YANQUN
Phase 3
90
Guangzhou
2024-05-15
Active, closed
Bristol-Myers Squibb
Phase 4
84
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanchang
2024-05-15
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
36
Guangzhou, Wuhan, Changsha
2024-05-15
Recruiting
Prebiotics and the Management of Hyperuricemia
NCT06420401Subjects With Hyperuricemia
Sun Yat-sen University
Not applicable
160
Guangzhou
2024-05-15
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
30
Beijing, Guangzhou, Shanghai, Shenzhen
2024-05-14
Recruiting
Dizal Pharmaceuticals
Phase 3
218
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-05-13
Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Not applicable
20
Guangzhou
2024-05-11
Recruiting
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
NCT06196294Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2024-05-10
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
274
Guangzhou
2024-05-08
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2024-05-08
Active, closed
Bio-Thera Solutions
Phase 1/2
218
Guangzhou
2024-05-08
Rows per page Showing 1501–2000 of 3345
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,345 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,977 of the 3,345 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 479 have not yet opened recruitment, 820 are active but closed to new participants, and 69 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.